FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
The AHA wrapped up its inaugural Healthier Together Conference in Dallas May 14 with a plenary session on how the application of artificial intelligence-driven…
Headline
The Medicaid and CHIP Payment and Access Commission approved recommendations it will issue to Congress in its June report on oversight and increased…
Headline
John Riggi, AHA national advisor for cybersecurity and risk, will moderate a webinar May 5 at 1 p.m. ET that will explore how bad actors are leveraging…
Headline
The Cybersecurity and Infrastructure Security Agency, National Security Agency and international partners have released guidance on adopting agentic artificial…
Headline
The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply…
Headline
Jim VandeHei, CEO of Axios; Marc Boom, M.D., AHA board chair and president and CEO of Houston Methodist; Anne Klibanski, M.D., president and CEO of Mass…